VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Diagnosis of emphysema confirmed by CT scan. If a  │ Diagnosis of emphysema confirmed by CT scan. If a  │     100 │
│ report of past CT scan is not available at site    │ report of past CT scan is not available at site    │         │
│ documenting then a CT scan is to be performed at   │ documenting then a CT scan is to be performed at   │         │
│ screening                                          │ screening                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Male or female patients at least 18 years of age   │ Male or female patients at least 18 years of age   │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Able and willing to sign an informed consent       │ Able and willing to sign an informed consent       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient with record of congenital AAT deficiency   │ Patient with record of congenital AAT deficiency   │     100 │
│ of phenotype PiZZ (homozygote) or other rare       │ of phenotype PiZZ (homozygote) or other rare       │         │
│ phenotypes related to AAT deficiency and with AAT  │ phenotypes related to AAT deficiency and with AAT  │         │
│ serum level ≤ 11 micromole. For patients receiving │ serum level ≤ 11 micromole. For patients receiving │         │
│ IV AAT augmentation therapy the serum AAT level    │ IV AAT augmentation therapy the serum AAT level    │         │
│ threshold does not apply                           │ threshold does not apply                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of at least two moderate or severe         │ History of at least two moderate or severe         │     100 │
│ exacerbations that required change in treatment    │ exacerbations that required change in treatment    │         │
│ (antibiotics, systemic steroids, hospitalization)  │ (antibiotics, systemic steroids, hospitalization)  │         │
│ in the last 18 months prior to date of screening , │ in the last 18 months prior to date of screening , │         │
│ with at least one of these occurring within the    │ with at least one of these occurring within the    │         │
│ last 12 months prior to screening                  │ last 12 months prior to screening                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Ability to comply with completion of electronic    │ Ability to comply with completion of electronic    │     100 │
│ diary                                              │ diary                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Ability to self-administer inhaled AAT             │ Ability to self-administer inhaled AAT             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ No significant abnormalities in serum hematology,  │ No significant abnormalities in serum hematology,  │     100 │
│ serum chemistry and serum inflammatory /           │ serum chemistry and serum inflammatory /           │         │
│ immunogenic markers according to the Principal     │ immunogenic markers according to the Principal     │         │
│ Investigator's judgment, taking into               │ Investigator's judgment, taking into               │         │
│ considerations the potential effects of the AAT    │ considerations the potential effects of the AAT    │         │
│ deficiency                                         │ deficiency                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ No significant abnormalities in urinalysis         │ No significant abnormalities in urinalysis         │     100 │
│ according to the Principal Investigator's          │ according to the Principal Investigator's          │         │
│ judgment, taking into considerations the potential │ judgment, taking into considerations the potential │         │
│ effects of the AAT deficiency                      │ effects of the AAT deficiency                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ No significant abnormalities in ECG per            │ No significant abnormalities in ECG per            │     100 │
│ investigator judgment                              │ investigator judgment                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Negative for HBsAg and for antibodies to HCV,      │ Negative for HBsAg and for antibodies to HCV,      │     100 │
│ HIV-1                                              │ HIV-1                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ AAT deficient patients who are either naïve (not   │ AAT deficient patients who are either naïve (not   │     100 │
│ receiving IV augmentation therapy) or AAT          │ receiving IV augmentation therapy) or AAT          │         │
│ deficient patients (receiving IV augmentation      │ deficient patients (receiving IV augmentation      │         │
│ therapy), if they have been stable on regular      │ therapy), if they have been stable on regular      │         │
│ therapy for at least 3 months prior to the         │ therapy for at least 3 months prior to the         │         │
│ screening visit and are willing to continue the    │ screening visit and are willing to continue the    │         │
│ same regime throughout this trial. Note that only  │ same regime throughout this trial. Note that only  │         │
│ sites in Germany can recruit patients who are      │ sites in Germany can recruit patients who are      │         │
│ currently being treated with IV AAT.Patients who   │ currently being treated with IV AAT.Patients who   │         │
│ stopped IV augmentation treatment 6 months prior   │ stopped IV augmentation treatment 6 months prior   │         │
│ to screening date and will not re-start this       │ to screening date and will not re-start this       │         │
│ treatment for the course of the study will be      │ treatment for the course of the study will be      │         │
│ considered Naïve                                   │ considered Naïve                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Non-pregnant, non-lactating female patients, whose │ Non-pregnant, non-lactating female patients, whose │     100 │
│ screening pregnancy test is negative and who are   │ screening pregnancy test is negative and who are   │         │
│ using contraceptive methods deemed reliable by the │ using contraceptive methods deemed reliable by the │         │
│ investigator, or who are at least 2 years post-    │ investigator, or who are at least 2 years post-    │         │
│ menopausal or surgically sterilized                │ menopausal or surgically sterilized                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of lung transplant                         │ History of lung transplant                         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any lung surgery within the past two years         │ Any lung surgery within the past two years         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ On any thoracic surgery waiting list               │ On any thoracic surgery waiting list               │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ End of last exacerbation less than 6 weeks prior   │ End of last exacerbation less than 6 weeks prior   │     100 │
│ to screening/re-screening visit                    │ to screening/re-screening visit                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Clinically significant intercurrent illnesses      │ Clinically significant intercurrent illnesses      │     100 │
│ (except for respiratory or liver disease secondary │ (except for respiratory or liver disease secondary │         │
│ to AAT deficiency), including: cardiac, hepatic,   │ to AAT deficiency), including: cardiac, hepatic,   │         │
│ renal, endocrine, neurological, hematological,     │ renal, endocrine, neurological, hematological,     │         │
│ neoplastic, immunological, skeletal or other) that │ neoplastic, immunological, skeletal or other) that │         │
│ in the opinion of the investigator, could          │ in the opinion of the investigator, could          │         │
│ interfere with the safety, compliance or other     │ interfere with the safety, compliance or other     │         │
│ aspects of this study. Patients with well-         │ aspects of this study. Patients with well-         │         │
│ controlled, chronic diseases could possibly be     │ controlled, chronic diseases could possibly be     │         │
│ included after consultation with the treating      │ included after consultation with the treating      │         │
│ physician and the sponsor                          │ physician and the sponsor                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Active smoking during the last 12 months from      │ Active smoking during the last 12 months from      │     100 │
│ screening date                                     │ screening date                                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnancy or lactation                             │ Pregnancy or lactation                             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Woman of child-bearing potential not taking        │ Woman of child-bearing potential not taking        │     100 │
│ adequate contraception deemed reliable by the      │ adequate contraception deemed reliable by the      │         │
│ investigator                                       │ investigator                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Presence of psychiatric/ mental disorder or any    │ Presence of psychiatric/ mental disorder or any    │     100 │
│ other medical disorder which might impair the      │ other medical disorder which might impair the      │         │
│ patient's ability to give informed consent or to   │ patient's ability to give informed consent or to   │         │
│ comply with the requirements of the study protocol │ comply with the requirements of the study protocol │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Evidence of ongoing viral infection with HCV, HBV  │ Evidence of ongoing viral infection with HCV, HBV  │     100 │
│ and/or HIV                                         │ and/or HIV                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Evidence of alcohol abuse or history of alcohol    │ Evidence of alcohol abuse or history of alcohol    │     100 │
│ abuse or illegal and/or legally prescribed drugs   │ abuse or illegal and/or legally prescribed drugs   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ IgA Deficiency                                     │ IgA Deficiency                                     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of life threatening allergy, anaphylactic  │ History of life threatening allergy, anaphylactic  │     100 │
│ reaction, or systemic response to human plasma     │ reaction, or systemic response to human plasma     │         │
│ derived products                                   │ derived products                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participation in another clinical trial within 30  │ Participation in another clinical trial within 30  │     100 │
│ days prior to baseline visit                       │ days prior to baseline visit                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Inability to attend scheduled clinic visits and/or │ Inability to attend scheduled clinic visits and/or │     100 │
│ comply with the study protocol                     │ comply with the study protocol                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any other factor that, in the opinion of the       │ Any other factor that, in the opinion of the       │     100 │
│ investigator, would prevent the patient from       │ investigator, would prevent the patient from       │         │
│ complying with the requirements of the protocol    │ complying with the requirements of the protocol    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ FEV1/SVC\>=70%                                     │ FEV1/SVC>=70%                                      │      96 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ FEV1 \>= 80% or FEV1 \< 20% of predicted value     │ FEV1 >= 80% or FEV1 < 20% of predicted value post- │      98 │
│ post-bronchodilator                                │ bronchodilator                                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ FEV1/SVC \<70% of predicted value post             │ FEV1/SVC <70% of predicted value post              │      99 │
│ bronchodilator (SVC is slow VC) and FEV1 \< 80% of │ bronchodilator (SVC is slow VC) and FEV1 < 80% of  │         │
│ predicted value post-bronchodilator                │ predicted value post-bronchodilator                │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤══════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                                    │   Score │
╞═══════════════════════════════════╪══════════════════════════════════════════════════╪═════════╡
│ Principal                         │ Pregnancy or lactation                           │      32 │
├───────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years │ Male or female patients at least 18 years of age │      44 │
╘═══════════════════════════════════╧══════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 96.1470588235294
OverAll Ratio: 97.5735294117647
